1560 studies found for:    Open Studies | "Lymphatic Diseases"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Lymphatic Diseases"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders
Conditions: Lymphedema;   Lymphatic Disorders;   Lipedema;   Vascular Malformation;   Vascular Anomaly
Intervention: Drug: NIRFLI with ICG
2 Recruiting National Lymphatic Disease and Lymphedema Registry
Condition: Lymphedema
Intervention:
3 Unknown  Study of Autoimmune Lymphoproliferative Syndrome (ALPS)
Conditions: Autoimmune Disease;   Lymphatic Disease;   Lymphoproliferative Disorder;   Canale-Smith Syndrome
Intervention:
4 Recruiting Sildenafil for the Treatment of Lymphatic Malformations
Conditions: Lymphatic Malformations;   Lymphatic Diseases
Interventions: Drug: Sildenafil 20 mg tablets;   Other: Placebo tablets (resembling Revatio)
5 Recruiting Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
Conditions: Lymphatic Diseases;   Hematopoietic Malignancy
Intervention: Biological: Umbilical Cord Blood (UCB)
6 Recruiting Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
Conditions: Lymphangiomatosis;   Lymphedema;   Lymphangiectasia;   Pulmonary Lymphangiectasia
Intervention:
7 Recruiting Combination Chemotherapy or 90-Yttrium Ibritumomab Tiuxetan and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Relapsed Diffuse Large B-cell Non-Hodgkin Lymphoma
Conditions: Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Radiation: Yttrium Y 90 Ibritumomab tiuxetan;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Biological: Rituximab;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis
8 Recruiting Study Evaluating Venetoclax in Subjects With Relapsed or Refractory Non-hodgkin Lymphoma or Multiple Myeloma
Conditions: Non-Hodgkin Lymphoma;   Multiple Myeloma
Intervention: Drug: venetoclax
9 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
10 Unknown  TREatment of degeNerative and Neoplastic Diseases With Rituximab
Condition: Diffuse Large B Cell Lymphoma
Intervention: Biological: Rituximab
11 Recruiting Bronchoscopic Sampling Techniques in Sarcoidosis
Conditions: Mediastinal Lymph Node Enlargement;   Sarcoidosis;   Tuberculosis;   Lymphomas
Interventions: Procedure: EBUS guided transbronchial forceps biopsy (EBUS-TBFB);   Procedure: EBUS guided transbronchial needle aspiration (EBUS-TBNA);   Procedure: large bore (19G) histologic needle biopsy of the mediastinal lymph nodes;   Procedure: Bronchoalveolar lavage (BAL);   Procedure: Endobronchial forceps biopsy
12 Unknown  Ultrasonographic Differentiation Between Kikuchi's Disease and Lymphoma in Patients With Cervical Lymphadenopathy
Conditions: Lymphoma;   Kikuchi's Disease
Intervention:
13 Not yet recruiting Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Conditions: Recurrent Mantle Cell Lymphoma;   Refractory Mantle Cell Lymphoma
Interventions: Drug: Enzalutamide;   Other: Laboratory Biomarker Analysis
14 Recruiting Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas
Conditions: DLBCL;   MCL;   Recurrent Disease
Intervention: Drug: 90Y-DOTATOC
15 Recruiting Diagnostic Qualities of the Positron Emission Tomography Coupled to the Scanner (PET / CT) in the Assessment of Response to Non-Hodgkin's Lymphoma Therapy in Children and Adolescents
Condition: Non-Hodgkin Lymphoma
Intervention: Device: PET / CT
16 Not yet recruiting A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib
Condition: Systemic Anaplastic Large-Cell Lymphoma
Intervention: Drug: crizotinib
17 Not yet recruiting COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC
Condition: Lymphangioleiomyomatosis (LAM)
Intervention: Drug: Celecoxib
18 Not yet recruiting TORC1/2 Inhibitor INK128 in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
Condition: Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: TORC1/2 Inhibitor INK128
19 Not yet recruiting Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies
Conditions: Adult Burkitt Lymphoma;   Adult Diffuse Large B-Cell Lymphoma;   CD20-Positive Neoplastic Cells Present;   Indolent Adult Non-Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Refractory Mature B-Cell Non-Hodgkin Lymphoma
Interventions: Biological: Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein;   Radiation: indium In 111-DOTA-biotin;   Radiation: yttrium Y 90 DOTA-biotin;   Drug: Clearing Agent;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
20 Not yet recruiting Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Adult Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   MYC Gene Mutation;   Plasmablastic Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Prednisone;   Biological: Rituximab;   Drug: Therapeutic Hydrocortisone;   Drug: Vincristine Sulfate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years